OTC cannabidiol 'a risk for drug-drug adverse reactions'
A plan to make cannabidiol available over the counter comes with the risk that drug-drug interactions will not be monitored, a leading pharmacologist says.
This week the TGA unveiled its plan to let pharmacists prescribe low-dose cannabidiol from 2021, assuming manufacturers have had cannabidiol products registered in the meantime.
Medicinal cannabis products are currently limited to the Special Access Scheme.
Under the TGA's plan,